REHOVOT, Israel, Jan. 24,
2023 /PRNewswire/ -- Biomica
Ltd., a clinical-stage biopharmaceutical company
developing innovative microbiome-based therapeutics, and a
subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), today
announced its CEO and VP R&D will both be participating in
7th Annual Microbiome Movement Drug Development Europe,
taking place in London, UK,
between January 31 and February 2,
2023.
The 7th Microbiome Movement – Drug Development Summit
Europe aims to unite Europe's
leading drug developers and microbiome experts to share their
latest discoveries on microbiome functionality, translation,
clinical development, biomarker discovery and manufacturing
scale-up. In attendance from Biomica will be CEO Dr. Elran Haber
and VP R&D Dr. Shiri Meshner.
Dr. Haber will take part in two industry panel discussions.
These are entitled, "How to Turn Outstanding Microbiome Science
into Effective & Efficient Products", taking place on
February 1, 2023, at 9:30am GMT and "Working with Microbiome
Investors", scheduled to take place later that day at
4:30pm GMT.
Dr. Meshner will be presenting on February 1, 2023, at 2:55pm, and the presentation is entitled,
"Rationally Designed LBPs – From Computational &
Pre-clinical Data to Clinical Studies."
Dr. Haber and Dr. Meshner will both be available for one-on-one
meetings at the conference, and those interested should be in touch
with the investor or public relations team.
About Biomica
Biomica is a clinical-stage biopharmaceutical company developing
innovative microbiome-based therapeutics utilizing a dedicated
Computational Predictive Biology platform (CPB), licensed from
Evogene. Biomica aims to identify and characterize disease-related
microbiome entities and to develop novel therapeutics based on
these understandings. The company is focused on the development of
therapies for antibiotic resistant bacteria, immuno-oncology, and
microbiome-related gastrointestinal (GI) disorders. Biomica is a
subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN). For more
information, please visit www.biomicamed.com.
Logo -
https://mma.prnewswire.com/media/1974949/Biomica.jpg
Logo - https://mma.prnewswire.com/media/1947468/Evogene.jpg
Evogene Contacts:
Investor Relations
Kenny Green
Email: kenny.green@evogene.com
Tel: +1 212 378 8040
Public Relations:
Lital Mamon
Email: lital.mamon@evogene.com
Tel: +972 8 931 2097
View original
content:https://www.prnewswire.com/news-releases/biomica-ceo-to-participate-in-panel-discussion-at-7th-european-annual-microbiome-movement-301729122.html
SOURCE Biomica Ltd.